08 September 2010
Keywords: Amarin, Ethyl Eicosapent, EMEA, MA withdrawal, Huntington's disease
Article | 9 December 2009
The European Medicines Agency (EMEA) says it has been formally notified by Ireland-based Amarin Neuroscience of its decision to withdraw its application for a centralized marketing authorization for Ethyl Eicosapent (ethyl eicosapent), 500mg soft gelatine capsules.
E Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.